Why the study?
Does nose-to-brain delivery of Compound 21 reduce cerebral infarct size and improve neurological scores in rats with ischemic stroke?
Does nose-to-brain delivery of Compound 21 reduce cerebral infarct size and improve neurological scores in rats with ischemic stroke?
Nose-to-brain delivery of the AT2 receptor agonist Compound 21 bypasses the blood-brain barrier to provide neuroprotection and reduce infarct size in a rat model of ischemic stroke.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for N2B C21 in rodent stroke; leaves open translation to human ischemic stroke.
Significant neuroprotective effects of angiotensin II type 2 (AT2) receptor (AT2 receptor) agonists in ischemic stroke have been previously demonstrated in multiple studies. However, the routes of agonist application used in these pre-clinical studies, direct intracerebroventricular (ICV) and systemic administration, are unsuitable for translation into humans; in the latter case because AT2 receptor agonists are blood–brain barrier (BBB) impermeable. To circumvent this problem, in the current study we utilized the nose-to-brain (N2B) route of administration to bypass the BBB and deliver the selective AT2 receptor agonist Compound 21 (C21) to naïve rats or rats that had undergone endothelin 1 (ET-1)-induced ischemic stroke. The results obtained from the present study indicated that C21 applied N2B entered the cerebral cortex and striatum within 30 min in amounts that are therapeutically relevant (8.4–9 nM), regardless of whether BBB was intact or disintegrated. C21 was first applied N2B at 1.5 h after stroke indeed provided neuroprotection, as evidenced by a highly significant, 57% reduction in cerebral infarct size and significant improvements in Bederson and Garcia neurological scores. N2B-administered C21 did not affect blood pressure or heart rate. Thus, these data provide proof-of-principle for the idea that N2B application of an AT2 receptor agonist can exert neuroprotective actions when administered following ischemic stroke. Since N2B delivery of other agents has been shown to be effective in certain human central nervous system diseases, the N2B application of AT2 receptor agonists may become a viable mode of delivering these neuroprotective agents for human ischemic stroke patients.
No takes yet. Share an insight, caveat, or question.
Bennion et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: